|
||||||
|
 |
|||
|
 |
Richard C. Faint, Jr. Mr. Faint is CEO and Chairman of Impact Labs, an image compression and encryption software company. Before joining Impact, Mr. Faint was VP of Marketing for Citrix Systems, which he joined after Citrix acquired Sequoia Software, where he had been CEO. Mr. Faint joined Sequoia in 1996 and guided the company through three rounds of venture financing and its initial public offering (IPO) in May 2000. Prior to Sequoia, Mr. Faint participated in the management led acquisition of Performance Learning Group, which merged with Mergent Technologies Group. Mr. Faint served as CFO until the company's sale to Prentice-Hall, Inc. in April, 1996. From 1984 to 1994 Mr. Faint was a co-founder and CFO of PersonaCare until its merger with TheraTx. He remained with Theratx through its successful IPO and to its eventual sale to Vencor. Earlier in his career, Mr. Faint was an attorney practicing business law. He received a bachelors degree in accounting from Towson University, and an MBA and JD from University of Baltimore. Norman C. Frost, Jr. Mr. Frost has worked as an investment banker for over 20 years. He was a Managing Director of Legg Mason Wood Walker, Inc. and head of the firm’s Technology Sector in the Investment Banking Department. Mr. Frost began his career at The First Boston Corporation, spent several years as a Managing Director in the Communications Group at Bear, Stearns & Co. Inc. and as a Managing Director in the Telecommunications Group at Smith Barney, Inc. He has testified as an expert witness on telecommunication finance, been a frequent speaker on telecommunication finance and M&A issues at industry conferences, and also has been a contributor to industry publications. Edward L. Erickson Mr. Erickson, BS, MS, MBA, has extensive experience in the biomedical products industry having served as president, CEO and/or a director of six such companies, three of which successfully completed initial public offerings under his leadership. He was Chairman, President and CEO of Immunicon Corporation, which is engaged in the development and commercialization of specialized products in cancer diagnostics, cell therapy, and nucleic acid analysis. He is also a director of NaPro Biotherapeutics, a publicly traded pharmaceutical company (NPRO). From 1993-1998, Mr. Erickson was President and CEO of DepoTech Corporation (DEPO), a drug delivery company that he took public in 1995. From 1995-1998, he was also a director of Megabios Corporation (MBIO), a gene therapy company that completed an IPO in 1997. From 1991-1993, Mr. Erickson was President and CEO of Cholestech Corporation (CTEC), a cholesterol diagnostics company where he completed a successful turnaround and took the company public for one of 1992’s top ten best performing IPOs. Mr. Erickson also served in executive management positions in The Ares-Serono Group, a Swiss-based pharmaceutical company, and Amersham International (now Nycomed Amersham), a diversified international medical products company traded on the London Stock Exchange. Dr. Jennie Hunter-Cevera Dr. Hunter-Cevera has broad biotechnology experience that spans both academia and the corporate world. She is President of the University of Maryland Biotechnology Institute (UMBI). Prior to joining UMBI, Dr. Hunter-Cevera served as the head of the Center for Environmental Biotechnology at the Lawrence Berkeley National Laboratory, as the project manager for the California Institute of Food and Agriculture, and as research scientist and director for a number of commercial biotechnology and pharmaceutical companies, including E.R. Squibb, Cetus Corp, Geobiotics, Biosource Genetics, and Universal Flavors. Dr. Hunter-Cevera founded The Biotic Network, a consulting company where she worked with a number of emerging biotechnology companies and co-founded Blue Sky Research, a bioscience research company. She has served on the State Department’s Biotechnology Council for Genetically Modified Foods and as a member of Secretary Glickman’s Advisory Board on Genetic Resources as well as OCED’s Board on Biological Resources. Dr. Hunter-Cevera was elected to the American Academy of Microbiology in 1995, received the SIM Charles Porter Award in 1996, was elected a SIM Fellow in 1997 and named the Nath Lecturer at WVU in 1999, the WVU Distinguished Alumni in 2002 and one of the 100 top women in Maryland in 2003. Dr. Hunter-Cevera received her B.A. in Biology WVU in 1970. She received her M.S. in microbiology from WVU in 1972 and her Ph.D. in microbiology from Rutgers University in 1978. |